What medication is recommended for chronic pruritus due to uremia in a patient on Hemodialysis (HD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Chronic Uremic Pruritus in Hemodialysis Patients

Gabapentin (100-300 mg after each dialysis session, three times weekly) is the most effective medication for treating chronic pruritus due to uremia in hemodialysis patients. 1

First-Line Approach: Optimize Dialysis Parameters

Before initiating pharmacologic therapy, ensure:

  • Adequate dialysis (target Kt/V of around 1.6) as pruritus is more common in underdialysed patients 1, 2
  • Normalized calcium-phosphate balance and controlled parathyroid hormone levels 1, 2
  • Correction of anemia with erythropoietin if present 2
  • Regular use of emollients to address xerosis (dry skin), which is the most common cutaneous manifestation in dialysis patients 1, 2

Pharmacologic Treatment Algorithm

First-Line Medication

  • Gabapentin 100-300 mg after each dialysis session (three times weekly) 1
    • A multicentre, double-blind, placebo-controlled trial showed good response rates with 100 mg postdialysis, with visual analogue ratings falling by over 50% compared to placebo 1
    • Note that these are lower doses than used in non-ESRD populations due to reduced renal clearance 1
    • Common side effect: mild drowsiness 1

Alternative/Adjunctive Treatments

  • Topical capsaicin cream (0.025%) applied to affected areas 1, 2

    • Acts by depleting neuropeptides including substance P in peripheral sensory neurons 1
  • Topical calcipotriol for localized areas 1

  • Doxepin (10 mg twice daily) for short-term use 1

    • Complete resolution reported in 58% of patients vs. 8% on placebo 1
    • Caution: 50% of patients reported drowsiness 1
    • Avoid long-term use of sedative antihistamines due to potential dementia risk 1, 2

Important Considerations and Pitfalls

  • Avoid cetirizine (10 mg daily) as it has been shown ineffective specifically for uremic pruritus 1

  • Avoid long-term sedative antihistamines except in palliative situations, as they may predispose to dementia 1, 2

  • Ketotifen (1 mg daily) may be as effective as gabapentin according to one RCT, but has less supporting evidence overall 1

  • Renal transplantation remains the only definitive treatment for uremic pruritus but is not always feasible 1, 3

  • Pruritus severity monitoring is important as it significantly impacts quality of life and is associated with depression and mortality in hemodialysis patients 4

  • Despite its high prevalence (affecting 40-90% of hemodialysis patients), uremic pruritus remains underdiagnosed and undertreated, with approximately 17% of severely affected patients not reporting symptoms to healthcare providers 4

Treatment Resistance

For patients with refractory pruritus:

  • Consider UVB phototherapy if available 2, 3
  • In Japan, nalfurafine (a κ-opioid receptor agonist) has shown efficacy 5, 6
  • For suitable candidates with intractable symptoms, consider prioritizing for kidney transplantation 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for Pruritus in Chronic Kidney Disease (CKD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Uremic pruritus.

Kidney international, 2015

Research

International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.

Clinical journal of the American Society of Nephrology : CJASN, 2017

Guideline

Emergency Treatment for Pruritus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Uremic pruritus in chronic hemodialysis patients.

Journal of nephrology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.